vs

Side-by-side financial comparison of CME Group (CME) and Ingersoll Rand (IR). Click either name above to swap in a different company.

Ingersoll Rand is the larger business by last-quarter revenue ($2.1B vs $1.9B, roughly 1.1× CME Group). Ingersoll Rand runs the higher net margin — 12.7% vs 0.1%, a 12.7% gap on every dollar of revenue. On growth, CME Group posted the faster year-over-year revenue change (14.5% vs 10.1%). Over the past eight quarters, Ingersoll Rand's revenue compounded faster (11.9% CAGR vs 10.8%).

CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...

Ingersoll Rand Inc. is an American multinational company that provides flow creation and industrial products. The company was formed in February 2020 through the spinoff of the industrial segment of Ingersoll-Rand plc and its merger with Gardner Denver. Its products are sold under more than 40 brands across all major global markets.

CME vs IR — Head-to-Head

Bigger by revenue
IR
IR
1.1× larger
IR
$2.1B
$1.9B
CME
Growing faster (revenue YoY)
CME
CME
+4.3% gap
CME
14.5%
10.1%
IR
Higher net margin
IR
IR
12.7% more per $
IR
12.7%
0.1%
CME
Faster 2-yr revenue CAGR
IR
IR
Annualised
IR
11.9%
10.8%
CME

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CME
CME
IR
IR
Revenue
$1.9B
$2.1B
Net Profit
$1.2M
$266.1M
Gross Margin
42.6%
Operating Margin
0.1%
18.7%
Net Margin
0.1%
12.7%
Revenue YoY
14.5%
10.1%
Net Profit YoY
20.7%
15.8%
EPS (diluted)
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CME
CME
IR
IR
Q1 26
$1.9B
Q4 25
$1.6B
$2.1B
Q3 25
$1.5B
$2.0B
Q2 25
$1.7B
$1.9B
Q1 25
$1.6B
$1.7B
Q4 24
$1.5B
$1.9B
Q3 24
$1.6B
$1.9B
Q2 24
$1.5B
$1.8B
Net Profit
CME
CME
IR
IR
Q1 26
$1.2M
Q4 25
$1.2B
$266.1M
Q3 25
$908.0M
$244.1M
Q2 25
$1.0B
$-115.3M
Q1 25
$956.2M
$186.5M
Q4 24
$874.6M
$229.8M
Q3 24
$912.8M
$221.6M
Q2 24
$883.2M
$185.0M
Gross Margin
CME
CME
IR
IR
Q1 26
Q4 25
42.6%
Q3 25
43.7%
Q2 25
43.7%
Q1 25
44.6%
Q4 24
42.9%
Q3 24
43.8%
Q2 24
43.9%
Operating Margin
CME
CME
IR
IR
Q1 26
0.1%
Q4 25
61.8%
18.7%
Q3 25
63.3%
19.2%
Q2 25
66.7%
4.0%
Q1 25
67.5%
17.6%
Q4 24
62.1%
20.0%
Q3 24
64.6%
19.1%
Q2 24
65.3%
15.1%
Net Margin
CME
CME
IR
IR
Q1 26
0.1%
Q4 25
71.7%
12.7%
Q3 25
59.1%
12.5%
Q2 25
60.6%
-6.1%
Q1 25
58.2%
10.9%
Q4 24
57.3%
12.1%
Q3 24
57.6%
11.9%
Q2 24
57.6%
10.2%
EPS (diluted)
CME
CME
IR
IR
Q1 26
Q4 25
$3.24
$0.67
Q3 25
$2.49
$0.61
Q2 25
$2.81
$-0.29
Q1 25
$2.62
$0.46
Q4 24
$2.40
$0.57
Q3 24
$2.50
$0.54
Q2 24
$2.42
$0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CME
CME
IR
IR
Cash + ST InvestmentsLiquidity on hand
$2.4B
$1.2B
Total DebtLower is stronger
$3.4B
$4.8B
Stockholders' EquityBook value
$10.1B
Total Assets
$202.0B
$18.3B
Debt / EquityLower = less leverage
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CME
CME
IR
IR
Q1 26
$2.4B
Q4 25
$4.5B
$1.2B
Q3 25
$2.6B
$1.2B
Q2 25
$2.1B
$1.3B
Q1 25
$1.5B
$1.6B
Q4 24
$3.0B
$1.5B
Q3 24
$2.4B
$1.4B
Q2 24
$1.9B
$1.1B
Total Debt
CME
CME
IR
IR
Q1 26
$3.4B
Q4 25
$4.8B
Q3 25
$4.8B
Q2 25
$4.8B
Q1 25
$4.8B
Q4 24
$4.8B
Q3 24
$4.8B
Q2 24
$4.8B
Stockholders' Equity
CME
CME
IR
IR
Q1 26
Q4 25
$28.7B
$10.1B
Q3 25
$28.2B
$10.1B
Q2 25
$27.7B
$10.1B
Q1 25
$27.0B
$10.5B
Q4 24
$26.5B
$10.2B
Q3 24
$28.2B
$10.3B
Q2 24
$27.6B
$10.0B
Total Assets
CME
CME
IR
IR
Q1 26
$202.0B
Q4 25
$198.4B
$18.3B
Q3 25
$187.1B
$18.2B
Q2 25
$179.9B
$18.1B
Q1 25
$157.8B
$18.4B
Q4 24
$137.4B
$18.0B
Q3 24
$137.8B
$18.2B
Q2 24
$123.4B
$17.8B
Debt / Equity
CME
CME
IR
IR
Q1 26
Q4 25
0.47×
Q3 25
0.47×
Q2 25
0.47×
Q1 25
0.45×
Q4 24
0.47×
Q3 24
0.47×
Q2 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CME
CME
IR
IR
Operating Cash FlowLast quarter
$499.0M
Free Cash FlowOCF − Capex
$461.5M
FCF MarginFCF / Revenue
22.1%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.88×
TTM Free Cash FlowTrailing 4 quarters
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CME
CME
IR
IR
Q1 26
Q4 25
$1.1B
$499.0M
Q3 25
$968.1M
$354.6M
Q2 25
$1.1B
$245.7M
Q1 25
$1.1B
$256.4M
Q4 24
$1.0B
$526.2M
Q3 24
$1.0B
$404.0M
Q2 24
$776.9M
$304.9M
Free Cash Flow
CME
CME
IR
IR
Q1 26
Q4 25
$1.1B
$461.5M
Q3 25
$949.7M
$325.5M
Q2 25
$1.0B
$210.4M
Q1 25
$1.1B
$222.7M
Q4 24
$991.7M
$490.9M
Q3 24
$973.2M
$374.3M
Q2 24
$758.7M
$283.1M
FCF Margin
CME
CME
IR
IR
Q1 26
Q4 25
66.8%
22.1%
Q3 25
61.8%
16.6%
Q2 25
61.5%
11.1%
Q1 25
67.1%
13.0%
Q4 24
65.0%
25.9%
Q3 24
61.4%
20.1%
Q2 24
49.5%
15.7%
Capex Intensity
CME
CME
IR
IR
Q1 26
Q4 25
2.0%
1.8%
Q3 25
1.2%
1.5%
Q2 25
1.1%
1.9%
Q1 25
0.9%
2.0%
Q4 24
1.7%
1.9%
Q3 24
1.9%
1.6%
Q2 24
1.2%
1.2%
Cash Conversion
CME
CME
IR
IR
Q1 26
Q4 25
0.96×
1.88×
Q3 25
1.07×
1.45×
Q2 25
1.03×
Q1 25
1.17×
1.37×
Q4 24
1.16×
2.29×
Q3 24
1.10×
1.82×
Q2 24
0.88×
1.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CME
CME

Segment breakdown not available.

IR
IR

Transferred At Point In Time$1.5B71%
Transferred Over Time$193.0M9%
Precision And Science Technologies Segment$183.1M9%
Acquisitions In2024$175.6M8%
Acquisitions In2025$70.8M3%

Related Comparisons